Thus, it is conceivable that hemophilia A patients who express a dysfunctional FVIII protein, and are exposed to a therapeutic FVIII having a different amino acid sequence, could mount an immune response to the neo-epitope corresponding to this amino acid sequence (35). This evidence concerns the gene F8 and hemophilia A.